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No related serious adverse events were observed. The
eactogenicity proﬁle was comparable to that of the con-
rol vaccines. No increase in reactogenicity was observed:
n children compared with adults, or after the second or
hird dose compared with the ﬁrst. In both non-endemic and
ndemic populations, immune responses increased incre-
entally after each of the 3 doses of TDV and were balanced
gainst the 4 serotypes after 3 doses.
TDV was well tolerated and immunogenic in children in
oth endemic and non-endemic areas with a 3 dose sched-
le.
oi:10.1016/j.ijid.2010.02.1858
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ertussis surveillance and testing: Recommendations
rom the GPI
.H. Wirsing von König
HELIOS Klinikum Krefeld, Krefeld, Germany
The Global Pertussis Initiative (GPI) was established in
001 to evaluate the ongoing problem of pertussis worldwide
nd to recommend appropriate pertussis control strategies.
n addition to primary vaccinations, the GPI currently recom-
ends pertussis booster vaccination to pre-school children,
dolescents, and those adults at risk of transmitting Bor-
etella pertussis infection to infants. The GPI actively
ncourages efforts toward global standardization of pertus-
is disease clinical deﬁnitions and diagnostics. At a meeting
n Paris in January 2010, GPI members discussed pertussis
urveillance and testing, and prepared recommendations on
he implementation and utilization of these activities. Issues
nd projects discussed included:
Advantages and limitations of various national surveil-
lance systems;
Seroprevalence studies;
Ideal surveillance methodologies;
Ongoing efforts in standardization of real time PCR, cul-
ture, serology and sample treatment;
Likely future advances (eg, antibody detection in saliva).
Previous regional meetings of the GPI have conﬁrmed
hat many countries have limited laboratory facilities for
he detection of pertussis. The GPI hopes that the future
ntroduction of increased laboratory capabilities and greater
armonization of clinical deﬁnitions and detection methods
ill lead to enhanced surveillance and a better estimate of
he burden of pertussis infection worldwide.
oi:10.1016/j.ijid.2010.02.1859
6.004
dolescent and adult Pertussis vaccination programs: Are
hey having an impact?. Tan
Northwestern University, Chicago, IL, USA
Pertussis disease in infancy remains a signiﬁcant prob-
em, with a high risk of serious morbidity and mortality
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n both developed and developing countries. Improved dis-
ase prevention strategies are imperative. In countries with
stablished childhood vaccination programs, studies have
hown that adults are the predominant source of infec-
ion for infants. Therefore strategies to protect infants now
mphasise vaccination of adults, particularly those (eg, par-
nts, close household contacts and health-care workers) at
igh risk of transmitting infection to infants. A cocoon strat-
gy, in which all potential adolescent and adult contacts of
nfants are vaccinated, is probably the most cost-effective
olution.
Postpartum vaccination program of new mothers are
ngoing in the US. The introduction of booster doses in
dolescents has been an important step toward decreas-
ng disease burden. For example, in areas of Canada where
dap vaccine has been administered to 14- to 16-year-
lds, marked reductions of pertussis have been observed in
dolescents and younger age groups, possibly due to herd
mmunity.
Adult disease in itself is a concern, with the true adult
urden estimated at more than 600,000 cases annually in
he United States. Adults commonly have a persistent cough
or up to 4 months, often requiring medical treatment for
he associated morbidity and to reduce the risk of infec-
ion to others. Furthermore, it can have signiﬁcant ﬁnancial
mplications for the patient and society. Evidence suggests
hat implementation of adult vaccination programs could be
ighly cost-effective and even cost-saving. This presentation
ill review available data on pertussis vaccination of adults
nd adolescents, and assesses the potential impact of such
accination, both now and in the future.
oi:10.1016/j.ijid.2010.02.1860
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ick-borne encephalitis: Clinical Development of vaccines
or Children and Adults
.M. Pöllabauer ∗, A. Löw-Baselli, P.N. Barrett, H.J. Ehrlich
Baxter BioScience, Vienna, Austria
Tick-borne encephalitis virus (TBEV), a member of the
amily Flaviviridae, causes substantial morbidity and even
ortality in endemic areas. The distribution of TBEV cov-
rs many countries in Europe and large parts of central
nd eastern Asia. Although most infections with TBEV are
symptomatic, more than 10,000 severe cases are reported
nnually, and the incidence has increased considerably dur-
ng the last few decades. Up to 46% of patients are left
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immunogenicity met all licensure criteria, clinical efﬁcacy
was demonstrated and safety proﬁle was comparable to egg
derived vaccines1.14th International Congress on Infectious Diseases (ICID) Abs
with permanent sequelae such as cognitive or neuropsy-
chiatric complaints, dysphasia, hearing defects and spinal
paralysis. The severity of the disease and the lack of causal
therapy emphasize the need for prevention of tick borne
encephalitis (TBE) by vaccination. Inactivated, whole virus
TBE vaccines (FSME IMMUN, Baxter and Encepur, Novartis)
are widely used in Europe. In recent years a full clini-
cal development program, including safety, immunogenicity
and seropersistence studies has been conducted for FSME-
IMMUN in all age groups. Antigen doses of 2.4g and 1.2g
were identiﬁed as optimal for adults and children, respec-
tively. In an ongoing study, the safety and immunogenicity of
FSME-IMMUN 0.25ml Junior and Encepur 0.25ml Children are
being investigated in children 1 to 11 years of age. A total of
150 and 152 subjects were enrolled in the FSMEIMMUN and
Encepur group, respectively. Immunogenicity was assessed
by two different ELISA assays using antigens homologous to
the TBEV strains of either FSME IMMUN (IMMUNOZYM1), or
Encepur (Enzygnost2). Four weeks after the second vacci-
nation, in the FSME-IMMUN group, 100% of subjects were
seropositive in both the IMMUNOZYM- (>126 VIEU/ml) and
the Enzygnost ELISA (>10.32U/ml) compared with 94.0%
and 96.7% respectively, in the Encepur group. Geometric
mean concentrations (GMC) measured by IMMUNOZYM ELISA
were 3026 in the FSME-IMMUN and 678 in the Encepurgroup.
GMCs measured with the Enzygnost ELISA were 163.3 (FSME-
IMMUN) and 93.7 (Encepur). Local reactions after the 1st
vaccination occurred in 12.7% with FSME-IMMUN and in 28.9%
with Encepur. The rate of systemic reactions was compara-
ble: 9.3% (FSME-IMMUN) and 11.8% (Encepur). The presently
marketed TBE vaccines represent highly effective tools for
the prevention of this continuously spreading disease.
doi:10.1016/j.ijid.2010.02.1862
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Strategies for the Development of New Vaccines
S.A. Plotkin
University of Pennsylvania and Vaxconsult, Doylestown, PA,
USA
The reputation of vaccination rests on a two hundred
year old history of success against major infectious dis-
eases. In general, two achievements have been crucial to the
success of vaccines: the induction of long-lasting immuno-
logical memory in individuals and the stimulation of a herd
immunity that enhances control of infectious diseases in
populations. However, when one reviews the vaccines now
available it is apparent that most successes have been
obtained when the microbe has a bacteremic or viremic
phase during which it is susceptible to the action of neu-
tralizing antibodies, and before replication in the particular
organ to which it is tropic.Success has also been achieved against some agents repli-
cating on respiratory or gastrointestinal mucosae, against
which it has been possible to induce immune responses act-
ing locally as well as systemically.
1 IMMUNOZYM FSME IgG, Progen.
2 Enzygnost TBE, Dade Behring.
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Control of intracellular pathogens has not been achieved,
xcept partly with the BCG vaccine against tuberculosis,
nd modern efforts are directed towards pathogens against
hich cellular immune responses are critical.
Newer approaches in vaccine production such as nucleic
cid immunization, vectors, reverse genetics and additional
outes of administration may circumvent prior difﬁculties.
he target of vaccination will shift towards adolescents,
dults, patients in hospital and those with chronic diseases
nd possibly will extend to therapy as well as prevention.
he major scientiﬁc problems to be solved are maintenance
f immune memory, immaturity and post-maturity of the
mmune system, and adjuvants capable of stimulating selec-
ive cell types.
oi:10.1016/j.ijid.2010.02.1863
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ew Technology Update: Cell Culture derived seasonal
nd pandemic ﬂu vaccine
artmut J. Ehrlich ∗, P. Noel Barrett
Baxter Innovations GmbH, Vienna, Austria
The Vero cell line is the most widely accepted contin-
ous cell line by regulatory authorities and has been used
ince decades for the production of, e.g. polio-, rabies- and
otavirus vaccines. Here we report on the clinical charac-
erization of Vero cell derived inactivated pandemic- and
easonal inﬂuenza vaccines.
A whole virus H5N1vaccine based on (Viet-
am/1203/2004/H5N1, clade 1) was demonstrated to
e safe and had an excellent tolerability proﬁle. A dose
f 7.5 $g of a non-adjuvanted vaccine formulation was
ighly immunogenic and induced antibodies neutralizing
omologous strains as well as viruses from other H5N1
lades. A booster dose of a heterologous (clade 2) H5N1
accine 12-17 months later resulted in enhanced antibody
esponses against both the original (clade 1) and the booster
clade 2) strain, indicative of .cross-protective memory.
A vaccine against the current pandemic H1N1 strain is
eing studied in adults and children. In adults, two doses of
.5$g antigen induced seroprotective HA antibody titers in
9% - 91% of subjects. An ongoing pediatric study demon-
trated that after the second dose 100% seroprotection (HI
ssay) was attained in the 3-8 and 9-17 year old cohorts.
Vero cell derived trivalent seasonal inﬂuenza vaccines
split virion), using wildtype virus seed stocks were devel-
ped and extensively tested in human studies. Their1 This Project has been funded in whole with Federal (United
tates Government) funds from the Ofﬁce of the Assistant Secre-
ary for Preparedness and Response, Ofﬁce of Biomdical Advanced
esearch and Development Authority, under contract NUMBER
HS0100200600013C to DynPort Vaccine Company LLC, a CSC
ompany, under No.:S1008307 awarded to Baxter Healthcare Cor-
oration.
